Endovascular Stroke Therapy Trends From 2011 to 2017 Show Significant Improvement in Clinical and Economic Outcomes.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
07 2019
Historique:
pubmed: 21 5 2019
medline: 20 2 2020
entrez: 21 5 2019
Statut: ppublish

Résumé

Background and Purpose- The purpose of this study was to evaluate trends in length of stay, discharge status, and costs among patients with acute ischemic stroke who underwent endovascular therapy (ET) between 2011 and 2017. Methods- Using a retrospective observational study design, acute ischemic stroke patients undergoing ET from 2011 to 2017 were identified in the Premier Healthcare Database. The Mann-Kendall trend test was performed to examine clinical and economic outcomes trends. Results- Among the 505 824 acute ischemic stroke patients, 11 811(2.3%) were treated with ET. Patients receiving ET had a significant increase in home discharge and a significant decrease in mortality (17.7% to 29.6%, P<0.01; 21.6% to 12.8%, P<0.01). There was a significant decline in length of stay from 11.7 days to 8.7 days ( P<0.01). Total index admission costs declined ≈17% from 2011 to 2017 ($50 516.5-$42 026.9, P<0.01). Conclusions- Clinical and economic indicators significantly improved for acute ischemic stroke patients undergoing ET from 2011 to 2017.

Identifiants

pubmed: 31104618
doi: 10.1161/STROKEAHA.119.025112
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1902-1906

Auteurs

Ansaar T Rai (AT)

From the Cardiovascular and Specialty Solutions (C.C.), Johnson and Johnson.

Concetta Crivera (C)

From the Cardiovascular and Specialty Solutions (C.C.), Johnson and Johnson.

Iftekhar Kalsekar (I)

Medical Device Epidemiology (I.K.), Johnson and Johnson.

Rashmi Kumari (R)

Medical Device Epidemiology (R.K.), Johnson and Johnson.

Nataly Patino (N)

Medical Device Epidemiology (N.P.), Johnson and Johnson.

Farid Chekani (F)

Department of Neuroscience, Merck (F.C.).

Rahul Khanna (R)

MuSigma, Inc (R.K.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH